Literature DB >> 30955985

A Randomized, Placebo-Controlled Trial of Ibuprofen Plus Metaxalone, Tizanidine, or Baclofen for Acute Low Back Pain.

Benjamin W Friedman1, Eddie Irizarry2, Clemencia Solorzano3, Eleftheria Zias3, Scott Pearlman2, Andrew Wollowitz2, Michael P Jones2, Purvi D Shah2, E John Gallagher2.   

Abstract

STUDY
OBJECTIVE: Patients with low back pain are often treated with nonsteroidal anti-inflammatory drugs and skeletal muscle relaxants. We compare functional outcomes and pain among patients with acute low back pain who were randomized to a 1-week course of ibuprofen plus placebo versus ibuprofen plus 1 of 3 skeletal muscle relaxants: baclofen, metaxalone, and tizanidine.
METHODS: This was a randomized, double-blind, parallel-group, 4-arm study conducted in 2 urban emergency departments (EDs). Patients with nonradicular low back pain for less than or equal to 2 weeks were eligible if they had a score greater than 5 on the Roland-Morris Disability Questionnaire, a 24-item inventory of functional impairment caused by low back pain. All participants received 21 tablets of ibuprofen 600 mg, to be taken 3 times a day as needed. Additionally, they were randomized to baclofen 10 mg, metaxalone 400 mg, tizanidine 2 mg, or placebo. Participants were instructed to take 1 or 2 of these capsules 3 times a day as needed. All participants received a 10-minute educational session. The primary outcome was improvement on the Roland-Morris Disability Questionnaire between ED discharge and 1week later. Secondary outcomes included pain intensity 1 week after ED discharge (severe, moderate, mild, or none).
RESULTS: Three hundred twenty patients were randomized. One week later, the mean Roland-Morris Disability Questionnaire score of patients randomized to placebo improved by 11.1 points (95% confidence interval [CI] 9.0 to 13.3), baclofen by 10.6 points (95% CI 8.6 to 12.7), metaxalone by 10.1 points (95% CI 8.0 to 12.3), and tizanidine by 11.2 points (95% CI 9.2 to 13.2). At 1-week follow-up, 30% of placebo patients (95% CI 21% to 41%) reported moderate to severe low back pain versus 33% of baclofen patients (95% CI 24% to 44%), 37% of metaxalone patients (95% CI 27% to 48%), and 33% of tizanidine patients (95% CI 23% to 44%).
CONCLUSION: Adding baclofen, metaxalone, or tizanidine to ibuprofen does not appear to improve functioning or pain any more than placebo plus ibuprofen by 1 week after an ED visit for acute low back pain.
Copyright © 2019 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30955985      PMCID: PMC6756993          DOI: 10.1016/j.annemergmed.2019.02.017

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  22 in total

Review 1.  The Roland-Morris Disability Questionnaire and the Oswestry Disability Questionnaire.

Authors:  M Roland; J Fairbank
Journal:  Spine (Phila Pa 1976)       Date:  2000-12-15       Impact factor: 3.468

2.  A SECOND LOOK AT A SKELETAL MUSCLE RELAXANT: A DOUBLE-BLIND STUDY OF METAXALONE.

Authors:  K FATHIE
Journal:  Curr Ther Res Clin Exp       Date:  1964-11

3.  Diagnostic testing and treatment of low back pain in United States emergency departments: a national perspective.

Authors:  Benjamin W Friedman; Mikaela Chilstrom; Polly E Bijur; E John Gallagher
Journal:  Spine (Phila Pa 1976)       Date:  2010-11-15       Impact factor: 3.468

4.  Prescription of nonsteroidal anti-inflammatory drugs and muscle relaxants for back pain in the United States.

Authors:  Xuemei Luo; Ricardo Pietrobon; Lesley H Curtis; Lloyd A Hey
Journal:  Spine (Phila Pa 1976)       Date:  2004-12-01       Impact factor: 3.468

5.  Assessment of efficacy and psychomotor performances of thiocolchicoside and tizanidine in patients with acute low back pain.

Authors:  A Ketenci; E Ozcan; S Karamursel
Journal:  Int J Clin Pract       Date:  2005-07       Impact factor: 2.503

Review 6.  Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the cochrane collaboration.

Authors:  Maurits W van Tulder; Tony Touray; Andrea D Furlan; Sherra Solway; Lex M Bouter
Journal:  Spine (Phila Pa 1976)       Date:  2003-09-01       Impact factor: 3.468

Review 7.  A systematic review of the global prevalence of low back pain.

Authors:  Damian Hoy; Christopher Bain; Gail Williams; Lyn March; Peter Brooks; Fiona Blyth; Anthony Woolf; Theo Vos; Rachelle Buchbinder
Journal:  Arthritis Rheum       Date:  2012-01-09

Review 8.  Nonsteroidal anti-inflammatory drugs for low back pain: an updated Cochrane review.

Authors:  Pepijn D D M Roelofs; Rick A Deyo; Bart W Koes; Rob J P M Scholten; Maurits W van Tulder
Journal:  Spine (Phila Pa 1976)       Date:  2008-07-15       Impact factor: 3.468

9.  Aceclofenac-tizanidine in the treatment of acute low back pain: a double-blind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone.

Authors:  Anil Pareek; Nitin Chandurkar; A S Chandanwale; Ratnakar Ambade; Anil Gupta; Girish Bartakke
Journal:  Eur Spine J       Date:  2009-05-07       Impact factor: 3.134

10.  The Patient Health Questionnaire-2: validity of a two-item depression screener.

Authors:  Kurt Kroenke; Robert L Spitzer; Janet B W Williams
Journal:  Med Care       Date:  2003-11       Impact factor: 2.983

View more
  1 in total

1.  Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis.

Authors:  Aidan G Cashin; Thiago Folly; Matthew K Bagg; Michael A Wewege; Matthew D Jones; Michael C Ferraro; Hayley B Leake; Rodrigo R N Rizzo; Siobhan M Schabrun; Sylvia M Gustin; Richard Day; Christopher M Williams; James H McAuley
Journal:  BMJ       Date:  2021-07-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.